Tech Company Financing Transactions
Praxis Precision Medicines Funding Round
Praxis Precision Medicines, based in Cambridge, scored $110 million in funding from Eventide Asset Management, Adage Capital Management and Ample Plus Fund.
Transaction Overview
Company Name
Announced On
7/30/2020
Transaction Type
Venture Equity
Amount
$110,000,000
Round
Series C
Investors
Proceeds Purpose
Proceeds purposes were not disclosed.
Company Information
Company Status
Publicly-held
Industry
Biopharmaceutical
Mailing Address
1 Bdwy. 16th Floor
Cambridge, MA 02142
USA
Cambridge, MA 02142
USA
Phone
Website
Email Address
Overview
Praxis (Nasdaq: PRAX) is a genetic neuroscience company that develops high-impact therapies for patients and families affected by complex and debilitating brain disorders. At Praxis we get things done. Praxis is the process of using a theory or something that you have learned in a practical way.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Marcio Souza
Chief Financial Officer
Stuart Chaffee
Chief Medical Officer
Bernard Ravina
Chief Scientific Officer
Steven Petrou
Vice President
Karl Hansen
Vice President
Gabriel Martinez
Vice President
Rosa Tarng
Vice President
Marion Wittmann
Browse more venture capital transactions:
Prev: 7/30/2020: KloudGin venture capital transaction
Next: 7/30/2020: Ermetic venture capital transaction
Share this article
Where The Data Comes From
We do our best to report on all VC transactions involving tech companies. All VC database entries on this site are sourced from a variety of public sources. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs